Strategy analysis

July 15, 2019

2019 Post-ADA Report

July 22, 2019

Datamonitor Healthcare Strategy: Immuno-Oncology Deal Trends, 2014–18

Immuno-oncology continues to draw pharma companies to the deal table.

August 5, 2019

Big Pharma Licensing Trends, 2014–18

An analysis of the drug-focused licensing deals (out-licensing and in-licensing) made by Big Pharma companies shows an uptick in partnering from 2014 to 2015, followed by a slight decrease in 2016 that has held steady through 2018. Despite that slight decline, the peer set increased deal volume by roughly 15% between the beginning and the end of the five-year period. Total deal values rose even more, roughly 25%.

August 20, 2019

Spotlight on Antibody-Drug Conjugates

The first antibody-drug conjugate (ADC), Mylotarg, reached the market almost two decades ago. Since this time, the ADC field has undergone slow but transformative enhancements, with improvements to technologies and advancements in the pipeline leading to an invigoration of the field. The past couple of years have seen the approvals of three new ADCs: Polivy, Lumoxiti, and Besponsa, increasing the total number of ADCs approved by regulators worldwide to six. These approvals mark the start of a new era in which the ADC field is finally beginning to realize its full potential. With the ADC pipeline swelling to around 250 novel candidates in various stages of preclinical and clinical development, approvals for more ADCs appear firmly on the horizon.

September 20, 2019

Biosimilars in the US and Europe

Biosimilars have been available in Europe for over a decade, and have offered the opportunity to vastly reduce the cost of treatment for a large number of biologic agents.

June 25, 2019

Key Potential Drug Launches in 2021

July 24, 2020

Datamonitor Big Pharma Licensing Trends

This strategy report focuses on Big Pharma Licensing Trends with company analyses, case studies, therapy area analysis, and deal economics.

February 23, 2016

Mid Pharma Outlook

Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.

September 28, 2016

Innovation in Deal-Making

In order to continually and effectively compete with its peers, as well as with smaller specialty pharmaceutical companies and biotechnology companies, the top 20 global pharmaceutical peer set turns to deal-making as a means to balance out its internally developed portfolio, and to take advantage of the broader capabilities of partners or takeover targets.

June 13, 2018

Market Access Trends in Europe

Health technology assessments (HTAs) have become an integral part of procedures employed to inform new drug coverage and pricing decisions across Europe. Methodological approaches to HTA vary, however, while disparities are also apparent in the pertise and financial resources to conduct multidisciplinary assessments, and in the relative weight accorded to recommendations issued by national (or regional) HTA agencies (ICOM, 2017)

November 16, 2018

Access Trends in Emerging Markets

This report provides an in-depth analysis of the market access climate in emerging pharmaceutical markets. Focusing in particular on the E7 countries (Brazil, Russia, India, China, Mexico, Indonesia, and Turkey), it charts recent developments, assesses their potential impact on market access, and pinpoints areas in which further change is anticipated.

February 20, 2019

Gene Therapy Pipeline and Portfolio Analysis

Gene therapy has undergone transformative enhancements over the last 20 years, with improvements to technologies and advances in the pipeline that aim to invigorate the field in its second generation.

April 23, 2019

Vaccines Market Access in Emerging Markets

Emerging markets account for approximately 18% of the global vaccines market, which is valued at more than $24bn. However, there are indications that this is an underestimate, and some observers forecast that the overall marketplace will reach $50bn by the mid2020s.

August 29, 2019

2016 Post-AHA Report

The American Heart Association (AHA) Scientific Sessions 2016 was held in New Orleans, LA from November 12-16. The most interesting results were from PCSK9 inhibitors, with details from Repatha’s positive atherosclerosis imaging study and Phase II data.

December 12, 2016

Big Pharma Licensing Trends, 2011–15

Between 2011 and 2015, Big Pharma – a peer set of approximately 16 firms across the world with large R&D and sales organizations, and sales valued at $10bn or more – signed over 1,100 drug-focused deals, growing at a compound annual growth rate of 10%.

October 14, 2016

Immuno-Oncology Deal Trends, 2011–15

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated. The Big Pharma and Mid Pharma peer sets are an integral part of development and have been furthering efforts via deal-making.

October 14, 2016

CRO Snapshot: Clinical Outsourcing in 2012

By any standards, last year was a turbulent one for the pharmaceutical sector. The patent cliff claimed some of the industry’s most profitable properties and with the market share of these drugs losing ground to generics, put even more pressure on the top- and bottom-line performance of key players such as Eli Lilly and AstraZeneca, to name just two of the worst hit.

Such pressure – and the drive to cut fixed costs that goes with it – has been a boon for clinical CROs, which have become increasingly indispensable to the business of drug discovery, as clinical development is outsourced and specialist units, such as clinical laboratories, are offloaded to CROs in long-term guaranteed strategic partnerships.

Contract Research Organizations: Health and Wealth in 2013

For public contract research organizations (CROs), the financial story in 2013 was one of solid and steady growth. Revenues grew and company-estimated forecasts for 2014 are also positive.

CRO Snapshot 2013

An initial study of the only publicly available data detailing clinical trial starts where contract research organizations (CROs) were named as a collaborator in 2013 shows a 10% lessening in work to the service provider industry.

An Evolution in Partnering: Can CROs Lead the Way in Innovation?

The concept of a drug development partnership between CRO and sponsor is the latest strategic evolution in the search for efficiency and innovation in the biopharmaceutical world.

CMOs in China and India: Still the Places to be?

Low-cost and skilled workforces in China and India have positioned both countries as increasingly important manufacturing hubs for pharmaceutical companies, as they seek to contain costs while retaining quality outsourcing partners.

Despite the apparent inevitability of the contract manufacturing organization (CMO) sector’s growth in China and India, a recent wave of scandals has put significant dents in the reputations of both countries as locations for foreign firms to manufacture drugs. Rising costs have also caused some firms to question whether using one of the region’s many CMOs is worth the risk.

Disruptive Innovation and the Pharmaceutical Contract Services Sector

With the pharmaceutical sector currently in the middle of such a transformative cycle, are drug developers or the firms providing them with outsourced research or manufacturing services going to find themselves similarly left behind?

CMO Market Dynamics and Strategies

Commoditization in the CMO market is driving the leading players to niche services. The sector is struggling to deliver consistent growth.

Leading Players in the CMO Market

he following companies are the 10 largest small-molecule contract manufacturing organizations (CMOs) by revenue. While many of the firms also contain biologics businesses, where possible only the relevant small-molecule revenues have been counted.

The Contract Biomanufacturing Market Outlook to 2017

The biologic drug market is growing at nearly twice the pace of the overall pharmaceutical market, driven by major therapeutic fields under research such as oncology and autoimmune diseases. The forecasted 20% annual increase in biologic active pharmaceutical ingredient (API) demand between 2011 and 2017 combined with the growth of biosimilars will generate a positive environment for the biologics contract manufacturing organization (CMO) market to grow at 9% per year over the same period.

Surviving a Scandal: How to Expect the Unexpected

The Institute of Crisis Management defines a crisis as “any problem or disruption that triggers negative stakeholder reaction and that could impact the organization’s financial strength and ability to do what it does.” In the pharmaceutical setting, a crisis could mean an adverse clinical trial event, the bankruptcy of an essential service provider, or a serious product recall. It could be an event that is within the company’s control and has been mishandled, or an external situation that forces the business to change its strategic course, either temporarily or permanently.

CRO League Tables: Acquisition, Competition, and Privatization

Over the past 12 months, the clinical research outsourcing (CRO) industry has taken its next decisive steps in the evolution of a business making its mark in drug development.

Value-Based Pricing – Evolution Rather Than Revolution

A new value-based assessment (VBA) process is scheduled to come into effect in the UK in late 2014. There have been significant delays in determining how this would work in practice, reflecting VBA’s complexity.

November 4, 2016

PD-1/L1 Immunotherapies: Historical Sales and Market Trend Analysis Report

$7,500.00

Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) has outpaced Merck’s Keytruda (pembrolizumab) primarily
in non-small cell lung cancer (NSCLC) because of its early approval in squamous NSCLC, updated National
Comprehensive Cancer Network (NCCN) guidelines in 2015,

December 22, 2016